Homepage
Author:
NanoViricides
Posted Date:
May 26, 2026
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides
May 26, 2026
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides
May 19, 2026
Ebola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides
May 18, 2026
NanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase II
NanoViricides
May 15, 2026
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides
May 15, 2026
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides
May 11, 2026
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides
May 4, 2026
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
NanoViricides
April 21, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
NanoViricides
April 7, 2026
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
NanoViricides
April 1, 2026
1
2
Next
